摘要
目的:分析莫西沙星用于耐多药肺结核治疗的可行性。方法:检索PubMed、中国知网期刊全文数据库、中国生物医学文献数据库、万方数据库等数据库中所有以其他喹诺酮类药物作为对照的莫西沙星治疗耐多药肺结核的临床随机对照实验,采用Cochrane协作网提供的RevMan 4.2.10软件分析数据。结果:最终纳入5篇文献进行分析。结果表明莫西沙星治疗耐多药肺结核,痰菌转阴效果较同类药物好,病灶吸收和空洞闭合效果与同类药物相当;不良反应较同类药物相对较轻。结论:为了有效防治耐多药肺结核,减慢其对超广谱抗生素莫西沙星的耐药,临床医生应谨慎选用莫西沙星治疗耐多药肺结核。
Objective：To analyze the performance degree of moxifloxaci treatment multidrug resistance pulmonary tuberculosis. Methods：Retrieve all random control clinical trial through PubMed,China ZhiWang periodical full-text database,China biomedicine bibliographic database,WanFang database and so on.Date is analyzed by using the software Cochrane Collaboration＇s RevMan 4.2.10.Results： Five literatures are internalized.The results indicate that the effect of bacterium darkening in phlegm is better after cured by Moxifloxaci than other Quinolone drugs.focus of infection absorbing and cavity closing are fairly, and with light adverse drug reaction.Conclusion：In order to prevent and cure multidrug resistance pulmonary tuberculosis effectually,make it＇s resistant against super-broad-spectrum antibiotic Moxifloxaci slowly,doctor should use Moxifloxaci carefully to cure multidrug resistance pulmonary tuberculosis.
出处
《中国医药导刊》
2010年第9期1598-1599,共2页
Chinese Journal of Medicinal Guide
关键词
莫西沙星
耐多药肺结核
可行性分析
Moxifloxaci
Multidrug resistance pulmonary tuberculosis
Performance degree
